As a member of the Process Development, CMC group, the Sr. Scientist will contribute to the development and implementation of downstream purification processes to enable the advancement of Janux therapeutic candidates from Research through Clinical development. The successful job candidate will contribute to development, technical transfer of purification processes, and oversight of Contract Development and Manufacturing Organizations (CDMOs) for clinical manufacturing.
Essential Functions and Responsibilities:
- Point of contact for downstream communications to CDMO
- Review and edit Manufacturing Batch Records, Executed Batch Records and reports
- Assist in writing of regulatory filings
- Execute lab-scale process development and material generation activities to support pre-clinical studies and technical transfer to CDMOs
- Design and perform experiments under general supervision to identify and establish operating and performance parameters for purification steps and overall processes
- Prepare SOPs and technical reports and maintain appropriate records of experiments in accordance with SOPs and guidance
- Responsible for operation and preventive maintenance of laboratory equipment
- Assist with protein inventory management
- Analyze and communicate experimental results to colleagues and supervisor and provide solutions to problems
- Collaborate across functional areas, maintaining a good rapport
- Other duties as deemed necessary
Required Skills and Qualifications:
- A bachelor’s degree and a minimum of 8 years, a master’s degree with a minimum of 6years, or a PhD with a minimum of 2 years of directly relevant industry experience in downstream process development of biologics is required.
- BSc, MSc or PhD in Biochemistry, Bioengineering, Cell and Molecular Biology, or a related discipline is preferred
- Strong knowledge of cGMP bioprocessing and experience working with CDMOs is required
- Demonstrated technical proficiency, scientific creativity, collaboration with others, and independent thought in suggesting experimental design is required
- The ideal candidate will have experience in the following:
- Downstream CDMO management
- AKTA Chromatography and filtration unit operations
- Large molecule/biologic drug development
- Authoring of SOP’s and technical reports
- Working knowledge of different modes of chromatography, types of resins, and column packing.
- Strong analytical skills with hands-on experience with SDS-PAGE, HPLC, Octet, and TFF/UFDF is strongly preferred.
- Ability to multi-task, prioritize projects, and troubleshoot process and equipment problems.
- Ability to work in a highly collaborative environment with rapidly evolving priorities.
- Excellent written and oral communication skills.
Job Type: Full-time
Benefits:
· 401K
· Medical insurance
· Dental insurance
· Vision insurance
· Supplemental disability insurance plans
· Flexible schedule
· Life insurance
· Flexible vacation
· Sick time
· Incentive stock option plan
· Relocation assistance
Schedule:
· Monday to Friday
Work authorization:
· United States (Required)
Additional Compensation:
· Annual targeted bonus X%
Work Location:
· On site (San Diego, CA)
EQUAL OPPORTUNITY EMPLOYER:
Janux Therapeutics, Inc. is an equal opportunity employer that is committed to providing a work environment free of harassment and discrimination based upon a protected category, as well as an environment free from retaliation for protected activity.
Notice to Recruiters and Third-Party Agencies
The Talent Acquisition team manages the recruitment and employment process for Janux. To protect the interests of all parties involved, Janux will only accept resumes from a recruiter once a fully-executed search agreement is in place. Agencies are hereby specifically directed not to contact Janux employees directly in an attempt to present candidates. Janux will consider any candidate for whom an Agency and/or Recruiter has submitted an unsolicited resume to have been referred, free of any charges or fees.
Top Skills
What We Do
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.